WomanCare Global to Create Global Access to Amphora® and Softcup™
Delivering quality, affordable products to women and girls
SAN DIEGO, CA ― WomanCare Global announced today that it has entered into a strategic alliance with Evofem, a California based bio-technology company. Through this alliance, WomanCare Global will provide sales, marketing and global distribution of Evofem’s products, including Amphora and Softcup. In addition, Saundra Pelletier, founding CEO of WomanCare Global, has been named as the new CEO of Evofem Inc.
Amphora, a vaginal gel approved by the FDA in 2004 as a lubricant, is currently undergoing the largest global clinical trial to date of a non-hormonal contraceptive vaginal gel. Through various studies, Amphora has shown potential to be effective in protecting against sexually transmitted infections (STIs) including HIV. Softcup is a personal care alternative to tampons and sanitary pads that can be worn for up to 12 hours. It’s body-friendly, in both disposable and reusable options, with no drying cotton or rayon fibers and no link to Toxic Shock Syndrome (TSS).
“We are so pleased to partner with Evofem to create global access to Softcup and contribute to the commercialization plans for Amphora,” said WomanCare Global CEO Saundra Pelletier. “These exciting reproductive health products offer women and girls innovation, new contraceptive choices and a safe way to manage their menses.”
“In a rapidly changing and interconnected world, it is public-private alliances that can create lasting results,” added WomanCare Global Board Member Gill Greer. “This strategic partnership between WomanCare Global and Evofem is a perfect example of maximizing a mission with sustainable practices.”